Abstract | BACKGROUND: AIMS: METHOD: Two-hundred and ninety patients with social phobia were assigned randomly to paroxetine (20-50 mg/day flexible dose) or placebo for 12 weeks of double-blind treatment. Primary efficacy outcomes were the Liebowitz Social Anxiety Scale (LSAS) total score (patient-rated) and the Clinical Global Impression (CGI) scale global improvement item. The secondary efficacy variables included CGI scale severity of illness score and the patient-rated Social Avoidance and Distress Scale. RESULTS:
Paroxetine produced a significantly greater reduction in LSAS total score (mean change from baseline: -29.4 v. -15.6; P < or = 0.001) and a greater proportion of responders (score < or = 2 on CGI global improvement) (65.7% v. 32.4%; P < 0.001) compared with placebo at the end of the 12-week study period. Both primary efficacy variables were statistically significant compared with placebo from week 4 onwards. Paroxetine was generally well tolerated. CONCLUSIONS:
|
Authors | D Baldwin, J Bobes, D J Stein, I Scharwächter, M Faure |
Journal | The British journal of psychiatry : the journal of mental science
(Br J Psychiatry)
Vol. 175
Pg. 120-6
(Aug 1999)
ISSN: 0007-1250 [Print] England |
PMID | 10627793
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antidepressive Agents, Second-Generation
- Paroxetine
|
Topics |
- Adolescent
- Adult
- Aged
- Antidepressive Agents, Second-Generation
(administration & dosage, adverse effects)
- Anxiety Disorders
(drug therapy)
- Double-Blind Method
- Female
- Humans
- Interpersonal Relations
- Male
- Middle Aged
- Paroxetine
(administration & dosage, adverse effects)
- Phobic Disorders
(drug therapy)
- Treatment Outcome
|